ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)

ARS Pharmaceuticals has reported Receivables - Other for 5 years, with the latest figure at $4.3 million in Q3 2025.

• Quarterly Receivables - Other rose 3109.77% year-over-year to $4.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.3 million (up 3109.77% YoY) and the FY2024 annual result came in at $1.2 million, up 88.96% from the prior year.
• Receivables - Other advanced to $4.3 million in Q3 2025 per SPRY's latest filing, from $2.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $4.3 million in Q3 2025 and troughed at $122000.0 in Q2 2024.
• A 5-year average of $839538.5 and a median of $307000.0 in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other plunged 65.04% in 2024, then surged 3109.77% in 2025.
• Over 5 years, Receivables - Other stood at $159000.0 in 2021, then soared by 33.96% to $213000.0 in 2022, then jumped by 206.1% to $652000.0 in 2023, then soared by 88.96% to $1.2 million in 2024, then soared by 246.51% to $4.3 million in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $4.3 million, $2.0 million, and $963000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.